Safety and effectiveness of ipragliflozin in elderly versus non-elderly Japanese type 2 diabetes mellitus patients: 12 month interim results of the STELLA-LONG TERM study

Keyphrases

• Old Japanese 100%
• Type 2 Diabetes Mellitus Patients 100%
• Ipragliflozin 100%
• STELLA 100%
• Non-elderly 100%
• Elderly Patients 83%
• Serious Adverse Drug Reaction 50%
• Type 2 Diabetes Mellitus (T2DM) 33%
• Type 2 Diabetic Patients 33%
• Real-world Clinical Practice 33%
• Body Mass Index 16%
• Elderly People 16%
• Japan 16%
• Japanese Patients 16%
• Hemoglobin A1c (HbA1c) 16%
• Age Groups 16%
• Adverse Drug Reaction 16%
• Post-marketing Surveillance 16%
• Safety Analysis 16%
• Efficacy Analysis 16%
• Nonelderly Patients 16%
• Glycated Hemoglobin A1c 16%
• Baseline HbA1c 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Ipragliflozin 100%
• Non Insulin Dependent Diabetes Mellitus 100%
• Adverse Drug Reaction 80%
• Hemoglobin A1c 60%
• Glycosylated Hemoglobin 20%
• Postmarketing Surveillance 20%
• Population Study 20%